medwireNews: ESMO has developed a Clinical Practice Guideline to aid physicians in managing patients with metastatic non-small-cell lung cancer (NSCLC) carrying driver mutations.
The recommendations cover topics such as diagnosis, staging and risk assessment, treatment, and follow-up and survivorship.
The bulk of the main article is given over to treatment options, which are organized by type of driver mutation, such as EGFR and BRAF mutations, ALK and ROS1 rearrangements, and RET fusions. There is also a section on other oncogenic drivers with available targeted therapies, including MET exon 14 skipping mutations and MET amplifications, HER2 exon 20 mutations, NTRK fusions, KRAS G12C mutations, and EGFR exon 20 insertions.
Similar to the guideline for non-oncogene addicted metastatic NSCLC that preceded the current document, there is a section focusing on special populations, such as older individuals and those with a performance status of 2 or higher.
The “[r]ecommendations are based on available scientific data and the authors’ collective expert opinion,” state the guideline authors in the Annals of Oncology, and they note that the document was developed in line with the ESMO standard operating procedures.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2023 Springer Healthcare Ltd, part of the Springer Nature Group